Shire “Encouraged” By Settlement Talks Over Adderall

Law360, New York (April 27, 2006, 12:00 AM EDT) -- After months of negotiations, U.K. drug maker Shire Pharmaceuticals said this week it remains optimistic about talks with Barr Laboratories to try to settle out of court a patent challenge to Shire’s blockbuster hyperactivity drug Adderall XR.

The two companies are involved in litigation concerning Barr's efforts to market a copycat version of Shire's Adderall XR prior to the expiration of the Shire patents, which are not set to expire until 2018.

The two companies have remained tight-lipped concerning the negotiations, which have been ongoing since...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.